JP2019202956A - Ｇｉｐ上昇抑制剤 - Google Patents
Ｇｉｐ上昇抑制剤 Download PDFInfo
- Publication number
- JP2019202956A JP2019202956A JP2018098734A JP2018098734A JP2019202956A JP 2019202956 A JP2019202956 A JP 2019202956A JP 2018098734 A JP2018098734 A JP 2018098734A JP 2018098734 A JP2018098734 A JP 2018098734A JP 2019202956 A JP2019202956 A JP 2019202956A
- Authority
- JP
- Japan
- Prior art keywords
- mannitol
- gip
- active ingredient
- food
- fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 73
- 235000010355 mannitol Nutrition 0.000 claims abstract description 64
- 229930195725 Mannitol Natural products 0.000 claims abstract description 57
- 239000000594 mannitol Substances 0.000 claims abstract description 57
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- 230000037149 energy metabolism Effects 0.000 claims description 20
- 230000002929 anti-fatigue Effects 0.000 claims description 17
- 150000002632 lipids Chemical class 0.000 claims description 15
- 210000002784 stomach Anatomy 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000001629 suppression Effects 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 235000005911 diet Nutrition 0.000 claims description 9
- 230000037213 diet Effects 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 5
- 235000018823 dietary intake Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 65
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 65
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 230000028327 secretion Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000027119 gastric acid secretion Effects 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- MRPXYRDSKAJHTH-UHFFFAOYSA-N 3-bromo-5-methyl-2-phenyl-1h-pyrazolo[1,5-a]pyrimidin-7-one Chemical compound BrC=1C2=NC(C)=CC(=O)N2NC=1C1=CC=CC=C1 MRPXYRDSKAJHTH-UHFFFAOYSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 101000886874 Mus musculus Gastric inhibitory polypeptide Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 241001168730 Simo Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- -1 softeners Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018098734A JP2019202956A (ja) | 2018-05-23 | 2018-05-23 | Ｇｉｐ上昇抑制剤 |
| EP19806677.1A EP3797763A4 (de) | 2018-05-23 | 2019-05-22 | Inhibitor für erhöhten gip-spiegel |
| PCT/JP2019/020290 WO2019225653A1 (ja) | 2018-05-23 | 2019-05-22 | Ｇｉｐ上昇抑制剤 |
| US17/057,392 US20210212959A1 (en) | 2018-05-23 | 2019-05-22 | Gip elevation inhibitor |
| CN201980034277.7A CN112153965A (zh) | 2018-05-23 | 2019-05-22 | Gip上升抑制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018098734A JP2019202956A (ja) | 2018-05-23 | 2018-05-23 | Ｇｉｐ上昇抑制剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2019202956A true JP2019202956A (ja) | 2019-11-28 |
Family
ID=68616970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018098734A Pending JP2019202956A (ja) | 2018-05-23 | 2018-05-23 | Ｇｉｐ上昇抑制剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210212959A1 (de) |
| EP (1) | EP3797763A4 (de) |
| JP (1) | JP2019202956A (de) |
| CN (1) | CN112153965A (de) |
| WO (1) | WO2019225653A1 (de) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104543680A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种抗疲劳、改善胃肠功能的保健食品及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0625001A (ja) | 1991-07-02 | 1994-02-01 | Tsumura & Co | 血管内皮増殖促進剤 |
| JPH08259445A (ja) * | 1995-01-27 | 1996-10-08 | Takeda Chem Ind Ltd | 胃排出能改善性医薬組成物 |
| US20030157107A1 (en) | 2000-05-16 | 2003-08-21 | Kazumasa Miyawaki | Agents for preventing or ameliorating insulin resistance and/or obesity |
| KR20030079604A (ko) * | 2002-04-04 | 2003-10-10 | 서왕식 | 숙취해독(宿醉解毒) 및 피로회복제(疲勞回復劑) 조성물 |
| US6855526B2 (en) * | 2002-05-15 | 2005-02-15 | The United States Of America As Represented By The Secretary Of Agriculture | Method for making mannitol with Lactobacillus intermedius |
| JP4865991B2 (ja) | 2004-02-18 | 2012-02-01 | 花王株式会社 | 共凝集抑制剤 |
| JP5119509B2 (ja) | 2006-05-18 | 2013-01-16 | ビーエイチエヌ株式会社 | 活動意欲向上剤 |
| JP4113242B1 (ja) * | 2007-01-10 | 2008-07-09 | 節子 竹田 | 消化器症状の防止剤 |
| CN104171972A (zh) * | 2014-07-08 | 2014-12-03 | 北京市营养源研究所 | 一种具有减肥塑形特性的无糖爆米花 |
-
2018
- 2018-05-23 JP JP2018098734A patent/JP2019202956A/ja active Pending
-
2019
- 2019-05-22 EP EP19806677.1A patent/EP3797763A4/de not_active Withdrawn
- 2019-05-22 CN CN201980034277.7A patent/CN112153965A/zh active Pending
- 2019-05-22 WO PCT/JP2019/020290 patent/WO2019225653A1/ja unknown
- 2019-05-22 US US17/057,392 patent/US20210212959A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104543680A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种抗疲劳、改善胃肠功能的保健食品及其制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| ACTA NEUROL. SCAND., vol. 98, JPN6022046978, 1998, pages 36 - 40, ISSN: 0005044090 * |
| J. PHYSIOL., vol. Vol.535.2, JPN6022046977, 2001, pages 601 - 610, ISSN: 0005044089 * |
| LEWIS, D. A. ET AL.: "Glucose stimulated release of gastric inhibitory polypeptide from hamster small intestine: an in vit", LIFE SCI., vol. 25, JPN6019031974, 1979, pages 673 - 678, XP025555962, ISSN: 0004914390, DOI: 10.1016/0024-3205(79)90508-3 * |
| O'DORISIO, THOMAS. M. ET AL.: "Mannitol and glucose: effects on gastric acid secretion and endogenous gastric inhibitory polypeptid", AM. J. DIG. DIS., vol. 23, no. 12, JPN6019031977, 1978, pages 1079 - 1083, XP009524977, ISSN: 0004914388, DOI: 10.1007/BF01072882 * |
| ガストール［エスエス製薬］, vol. [online], JPN6022019841, 2016, ISSN: 0004914389 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3797763A4 (de) | 2022-02-23 |
| CN112153965A (zh) | 2020-12-29 |
| EP3797763A1 (de) | 2021-03-31 |
| WO2019225653A1 (ja) | 2019-11-28 |
| US20210212959A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5877902B2 (ja) | バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用 | |
| JP5830030B2 (ja) | 筋タンパク質合成を刺激するための低カロリー高タンパク質栄養組成物 | |
| JP5778912B2 (ja) | Ｉｇｆ−１分泌促進剤 | |
| JPWO2018164221A1 (ja) | 筋線維化抑制用組成物 | |
| JP2022110113A (ja) | エンテロコッカス・フェカーリス、その培養液またはその死菌体を有効成分として含有する筋肉の減退、低下及び筋萎縮の予防、改善または治療用の薬学組成物、食品組成物及び食品添加剤 | |
| EP2879713B1 (de) | Verbindungen und ihre auswirkungen auf appetitregulierung und insulinsensitivität | |
| JP6157928B2 (ja) | 肝臓への脂肪蓄積抑制剤 | |
| JPWO2007114499A1 (ja) | 抗脂肪蓄積用組成物 | |
| JP2012171914A (ja) | Ｇｉｐ上昇抑制剤 | |
| JP2010222284A (ja) | 血中ｇｉｐ上昇抑制剤 | |
| WO2019225653A1 (ja) | Ｇｉｐ上昇抑制剤 | |
| KR101875705B1 (ko) | 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP5576699B2 (ja) | Ｇｉｐ上昇抑制剤 | |
| JP2008074745A (ja) | 血糖上昇抑制剤 | |
| US10632092B2 (en) | Composition for and method to increase serum adiponectin and reduce body fat | |
| WO2018101417A1 (ja) | Ｇｉｐ上昇抑制剤 | |
| JP2019189572A (ja) | 運動バランス向上剤、及び敏捷性向上剤 | |
| JP2010168399A (ja) | 血糖の上昇を抑制するための薬剤 | |
| JPWO2009144977A1 (ja) | 経口育毛用組成物 | |
| JP2009209088A (ja) | アスペルロシドまたはその類縁体を含む筋肉増強剤 | |
| WO2018101102A1 (ja) | 食後ｇｉｐ上昇抑制剤 | |
| KR20150131476A (ko) | 설포라판 유도체를 유효성분으로 함유하는 간질환 예방 및 치료용 조성물 | |
| WO2021065661A1 (ja) | 筋肉量の低下抑制、低下予防、維持、回復又は増加用組成物 | |
| JP2018087172A (ja) | 脂質燃焼促進剤 | |
| JP2010013395A (ja) | メタボリックシンドローム症状の予防又は改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230425 |